Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
AXGN
AXGN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AXGN News
Axogen Prices Upsized Public Offering of 4 Million Shares at $31 Each, Raising Approximately $124 Million
Jan 22 2026
Benzinga
Axogen (AXGN) Prices Upsized Offering of 4 Million Shares at $31, Raising Approximately $124 Million
Jan 22 2026
NASDAQ.COM
Axogen (AXGN) Prices Upsized Public Offering of 4M Shares at $31, Expected to Raise $124M
Jan 22 2026
seekingalpha
Axogen (AXGN) Plans $85M Public Offering to Repay Debt
Jan 21 2026
seekingalpha
Axogen CEO Michael D. Dale Sells 25,000 Shares for $750,000
Jan 14 2026
Fool
Axogen to Present at J.P. Morgan 2026 Healthcare Conference
Dec 17 2025
Globenewswire
ETFs on the Move This Monday: REMX, IHI
Dec 08 2025
NASDAQ.COM
Axogen Reaches New 52-Week Peak Following FDA Approval of Innovative Nerve Repair Therapy
Dec 04 2025
Benzinga
UiPath Shares Rise Approximately 9%; Check Out 20 Stocks Making Moves in Premarket Trading
Dec 04 2025
Benzinga
Axogen Receives FDA Approval for Avance Biologics License Application
Dec 04 2025
Globenewswire
Axogen Receives FDA Approval for AVANCE Biologics, Advancing Nerve Repair Technology
Dec 04 2025
Newsfilter
FDA Grants Approval for Axogen's AVANCE Nerve Allograft to Repair Peripheral Nerves
Dec 04 2025
NASDAQ.COM
Mizuho Begins Coverage of Axogen with Outperform Rating and Sets Price Target at $40
Dec 01 2025
Benzinga
Biotech Stocks Await FDA Verdict in December 2025
Nov 27 2025
NASDAQ.COM
Caterpillar Reports Positive Q3 Earnings, Alongside United Therapeutics, Centene, Fortive, and Other Major Stocks Rising on Wednesday
Oct 29 2025
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
Oct 18 2025
PRnewswire
Show More News
